Literature DB >> 17308076

Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression.

Megumi Iiizumi1, Sucharita Bandyopadhyay, Kounosuke Watabe.   

Abstract

Tumor metastases suppressor protein KAI1/CD82 is capable of blocking the tumor metastases without affecting the primary tumor formation, and its expression is significantly down-regulated in many types of human cancers. However, the exact molecular mechanism of the suppressor function of KAI1 remains elusive. Evidence from our laboratory supports a model in which tumor cells dislodge from the primary tumor and intravasate into the blood or lymphatic vessels followed by attachment to the endothelial cell surface whereby KAI1 interacts with the Duffy antigen receptor for chemokines (DARC) protein. This interaction transmits a senescent signal to cancer cells expressing KAI1, whereas cells that lost KAI1 expression can proliferate, potentially giving rise to metastases. Our model of the mechanism of action of KAI1 shows that metastasis suppressor activity can be dependent on interaction with host tissue and explains how KAI1 suppresses metastasis without affecting primary tumor formation. Taken together, in vitro and in vivo studies identify the KAI1-DARC interaction as a potential target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308076     DOI: 10.1158/0008-5472.CAN-06-3801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

2.  The DARC-CD82 axis discloses bone marrow macrophages as guardians of long-term hematopoietic stem cells quiescence.

Authors:  Alejandro Pérez-Fernández; Ángel Hernández-Hernández
Journal:  Stem Cell Investig       Date:  2016-09-01

Review 3.  Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.

Authors:  Matthew D Ringel
Journal:  Thyroid       Date:  2011-04-10       Impact factor: 6.568

Review 4.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

5.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  Normal viability of Kai1/Cd82 deficient mice.

Authors:  John I Risinger; Mary Custer; Lionel Feigenbaum; R Mark Simpson; Shelley B Hoover; Joshua D Webster; Gadisetti V R Chandramouli; Lino Tessarollo; J Carl Barrett
Journal:  Mol Carcinog       Date:  2013-02-08       Impact factor: 4.784

Review 7.  The role of metastasis suppressor genes in metastatic dormancy.

Authors:  Christine E Horak; Jong Heun Lee; Jean-Claude Marshall; S Martin Shreeve; Patricia S Steeg
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 8.  Role of chemokines in tumor growth.

Authors:  Dayanidhi Raman; Paige J Baugher; Yee Mon Thu; Ann Richmond
Journal:  Cancer Lett       Date:  2007-07-12       Impact factor: 8.679

Review 9.  Metastatic mechanisms in follicular cell-derived thyroid cancer.

Authors:  John E Phay; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2013-10-14       Impact factor: 5.678

Review 10.  Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.

Authors:  Neel Rajan; Tilak Khanal; Matthew D Ringel
Journal:  Endocrine       Date:  2020-08-11       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.